| Literature DB >> 31872017 |
Tip Pongsuvareeyakul1, Kittipat Charoenkwan2, Prapaporn Suprasert2, Surapan Khunamornpong1.
Abstract
•Primary signet ring cell carcinoma in ovarian mucinous tumor is rare.•The most important differential diagnosis is metastatic carcinoma.•We report a case of primary ovarian signet ring cell carcinoma in mucinous tumor.•Clinicopathological correlation is essential to establish the correct diagnosis.Entities:
Keywords: Krukenberg tumor; Mucinous borderline tumor; Neuroendocrine differentiation; Ovary; Signet ring cell carcinoma
Year: 2019 PMID: 31872017 PMCID: PMC6909212 DOI: 10.1016/j.gore.2019.100522
Source DB: PubMed Journal: Gynecol Oncol Rep ISSN: 2352-5789
Fig. 1Primary signet ring cell carcinoma in mucinous borderline ovarian tumor (A) Multiple locules of variable size that lined by mucinous epithelium. Note the papillary structure on cystic lining (Hematoxylin and Eosin stain, 4×). (B) The mucinous epithelium ranged from flat cuboidal cells (at the right side) to stratified epithelium with papillary growth (Hematoxylin and Eosin stain, 20×). (C) A well-circumscribed mural nodule of signet ring cell carcinoma (Hematoxylin and Eosin stain, 1.25×). (D) Numerous variable-sized groups of signet ring cells in cellular fibrous stroma (Hematoxylin and Eosin stain, 20×). (E) Small groups and individual signet ring cells with moderate to marked nuclear atypia (Hematoxylin and Eosin stain, 40×). (F) Intracytoplasmic mucin in signet ring cells (Mucicarmine stain, 20×). (G) Scattered neuroendocrine cells in mucinous epithelium highlighted by synaptophysin immunostain (20×).
Fig. 2Immunohistochemical stains of signet ring cell carcinoma (A) Diffuse and strong positivity for cytokeratin 7 (20×). (B) Positivity for CDX-2 with variable intensity (20×). (C) Positivity for synaptophysin with moderate to strong intensity (20×). (D) Positivity for chromogranin-A with moderate to strong intensity (20×).
Primary signet ring cell carcinoma arising in ovarian mucinous tumor.
| Authors | Age (years) | FIGO stage | Mucinous component | Size (cm) | Adjuvant treatment | Follow-up duration (months) | Patient outcomes | Autopsy | |
|---|---|---|---|---|---|---|---|---|---|
| Tumor mass | Signet component | ||||||||
| 27 | IA | Cystadenoma | 9 | 1 | No | 36 | NED | – | |
| 60 | IA | Adenofibroma | 9 | Microscopic foci | No | N/A | N/A | N/A | |
| 55 | IA | Intraepithelial carcinoma in borderline tumor | 27 | N/A | No | 8 | NED | – | |
| 24 | IIIC | Borderline tumor | 25 | N/A | CMT | 5 | DOC | None | |
| 60 | At least IIIB | Adenocarcinoma | 15 | 5 | CMT | N/A | N/A | N/A | |
| 38 | IC | Adenocarcinoma | 20 | 3 | N/A | N/A | N/A | N/A | |
| 54 | IA | Adenocarcinoma | 20.5 | N/A | No | 12 | NED | – | |
| Current case | 59 | IC2 | Borderline tumor | 24 | 3 | CMT | 11 | NED | – |
N/A, not available; CMT, chemotherapy; NED, no evidence of disease; DOC, dead of other causes.